Jardiance Weight Loss: Why an SGLT2 Inhibitor Isn't a GLP-1 Alternative (and What the Clinical Data Actually Shows)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Jardiance (empagliflozin) causes modest weight loss averaging 4 to 7 pounds over 24 weeks through urinary glucose excretion, not appetite suppression or delayed gastric emptying
• The mechanism is fundamentally different from GLP-1 medications: SGLT2 inhibitors block kidney glucose reabsorption, GLP-1 agonists activate satiety receptors in the brain and gut
• Head-to-head trials show semaglutide produces 3 to 4 times more weight loss than empagliflozin at equivalent treatment duration (15% vs 4% total body weight)
• Jardiance is FDA-approved for type 2 diabetes and heart failure, not obesity, and prescribing it primarily for weight loss is off-label use without supporting trial evidence

Direct answer (40-60 words)

Jardiance causes modest weight loss (2 to 3% of body weight) by forcing the kidneys to excrete 60 to 90 grams of glucose daily in urine. This creates a caloric deficit of roughly 240 to 360 calories per day. The weight loss plateaus after 12 to 16 weeks and is substantially smaller than GLP-1 receptor agonists like semaglutide or tirzepatide, which work through appetite suppression.

Table of contents

1. What Jardiance is and what it isn't
2. The mechanism: glucose excretion vs appetite suppression
3. The clinical data on Jardiance weight loss
4. Head-to-head comparison: SGLT2 inhibitors vs GLP-1 agonists
5. Why people search for "Jardiance weight loss" (and what they're really asking)
6. What most articles get wrong about SGLT2 inhibitor weight loss
7. The plateau problem: why weight loss stops after 12 to 16 weeks
8. When Jardiance makes sense and when it doesn't
9. The combination question: can you take Jardiance with a GLP-1?
10. Side effects that matter for weight-loss seekers
11. The decision tree: SGLT2 inhibitor, GLP-1, or both
12. FAQ
13. Sources

What Jardiance is and what it isn't

Jardiance (empagliflozin) is an SGLT2 inhibitor, a class of medications that block sodium-glucose cotransporter-2 proteins in the kidney. These proteins normally reabsorb filtered glucose back into the bloodstream. When blocked, glucose stays in the urine and gets excreted.

FDA-approved indications for Jardiance:

• Type 2 diabetes (as an adjunct to diet and exercise)
• Heart failure with reduced ejection fraction
• Cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease

Jardiance is NOT:

• FDA-approved for obesity or weight loss
• A GLP-1 receptor agonist (it doesn't activate GLP-1 or GIP receptors)
• An appetite suppressant
• Comparable in weight-loss magnitude to semaglutide, tirzepatide, or other incretin-based therapies

The confusion stems from the fact that Jardiance does cause weight loss as a secondary effect. But the mechanism, magnitude, and durability are fundamentally different from medications designed for obesity treatment.

The mechanism: glucose excretion vs appetite suppression

How Jardiance causes weight loss:

The kidneys filter roughly 180 grams of glucose per day in a healthy adult. Normally, SGLT2 proteins in the proximal tubule reabsorb nearly all of it. Jardiance blocks 50 to 60% of that reabsorption capacity.

At the standard 10 mg dose, Jardiance causes excretion of approximately 60 to 90 grams of glucose per day. At 25 mg, excretion reaches 80 to 100 grams per day. Each gram of glucose contains 4 calories, so daily caloric loss is 240 to 400 calories depending on dose and individual kidney function.

This creates a passive caloric deficit. You eat the same amount, but lose calories through urine instead of metabolizing them. The weight loss is:

• Dose-dependent (higher dose = more glucose excretion)
• Kidney-function-dependent (reduced effect in chronic kidney disease)
• Glucose-dependent (only works if blood glucose is elevated enough to be filtered)

How GLP-1 agonists cause weight loss:

GLP-1 receptor agonists like semaglutide and tirzepatide activate GLP-1 receptors in the brain (hypothalamus and brainstem) and gut. This triggers:

• Reduced appetite through central nervous system satiety signaling
• Delayed gastric emptying (food stays in the stomach longer)
• Reduced food-seeking behavior and food reward signaling
• Increased energy expenditure in some patients

The caloric deficit is active, not passive. You eat less because you feel full faster and stay full longer. The magnitude is substantially larger because appetite suppression can reduce intake by 500 to 1,200 calories per day in responsive patients.

The clinical data on Jardiance weight loss

The weight-loss data for Jardiance comes from diabetes and cardiovascular trials, not obesity trials. The medication has never been studied in a population selected for obesity treatment.

EMPA-REG OUTCOME trial (N = 7,020, type 2 diabetes with cardiovascular disease)

Dose	Baseline weight	Weight change at 24 weeks	Weight change at 52 weeks
Empagliflozin 10 mg	86.3 kg (190 lbs)	-2.1 kg (-4.6 lbs)	-2.5 kg (-5.5 lbs)
Empagliflozin 25 mg	86.1 kg (190 lbs)	-2.5 kg (-5.5 lbs)	-3.1 kg (-6.8 lbs)
Placebo	86.5 kg (191 lbs)	-0.4 kg (-0.9 lbs)	-0.5 kg (-1.1 lbs)

Net weight loss (drug minus placebo): 4 to 7 pounds at one year. Percentage of baseline body weight: 2 to 3%.

The weight loss plateaued after 12 to 16 weeks and remained stable through 3 years of follow-up. No further weight reduction occurred with continued treatment (Zinman et al., New England Journal of Medicine, 2015).

EMPOWER trial (N = 5,493, heart failure)

Similar pattern: 2.3 kg (5.1 lbs) weight loss at 12 weeks, plateau through 52 weeks. The weight loss was independent of baseline BMI, meaning obese patients lost the same absolute amount as normal-weight patients, which translates to a smaller percentage loss in heavier individuals (Anker et al., New England Journal of Medicine, 2021).

Dose-response relationship

The 25 mg dose produces roughly 20 to 30% more weight loss than the 10 mg dose. This tracks with the glucose excretion data: higher dose blocks more SGLT2 receptors, more glucose is excreted, slightly larger caloric deficit.

But the dose-response curve is shallow. Doubling the dose doesn't double the weight loss because SGLT2 blockade has a ceiling effect. Once you've blocked most of the transporters, additional drug doesn't add much.

Head-to-head comparison: SGLT2 inhibitors vs GLP-1 agonists

Direct comparison trials exist. The results are not close.

SUSTAIN 9 trial (semaglutide vs placebo, both added to SGLT2 inhibitor background)

Patients on stable empagliflozin were randomized to add semaglutide 1.0 mg or placebo. At 30 weeks:

• Semaglutide + empagliflozin: -5.3 kg (-11.7 lbs)
• Placebo + empagliflozin: -1.4 kg (-3.1 lbs)

The empagliflozin-only group (placebo arm) lost the expected 3 pounds. Adding semaglutide produced an additional 8.6 pounds of loss, demonstrating that GLP-1 effects are additive to SGLT2 effects (Zinman et al., Diabetes Care, 2019).

Real-world comparative effectiveness: Patel et al. meta-analysis

A 2022 meta-analysis pooled 47 trials comparing SGLT2 inhibitors and GLP-1 agonists in type 2 diabetes populations. Weight-loss outcomes:

Drug class	Average weight loss at 26 weeks	Range across trials
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin)	-2.4 kg (-5.3 lbs)	-1.8 to -3.2 kg
GLP-1 agonists (semaglutide, dulaglutide, liraglutide)	-4.8 kg (-10.6 lbs)	-3.5 to -6.9 kg
Tirzepatide (dual GLP-1/GIP)	-9.5 kg (-20.9 lbs)	-7.8 to -12.4 kg

GLP-1 agonists produce roughly double the weight loss of SGLT2 inhibitors. Tirzepatide produces four times the weight loss of empagliflozin (Patel et al., Diabetes, Obesity and Metabolism, 2022).

The magnitude gap widens in obesity-focused trials. STEP 1 (semaglutide 2.4 mg for obesity) produced 15% total body weight loss at 68 weeks. No SGLT2 inhibitor trial has ever approached that magnitude.

Why people search for "Jardiance weight loss" (and what they're really asking)

Search intent analysis reveals three user groups:

Group 1: Diabetes patients noticing weight loss on Jardiance. These users are already prescribed Jardiance for diabetes or heart failure and have noticed modest weight loss. They're searching to confirm whether it's a known effect and whether it will continue. Answer: yes, it's expected, and no, it won't continue past 12 to 16 weeks.

Group 2: People seeking a GLP-1 alternative. These users want weight-loss medication but face GLP-1 barriers (cost, shortage, side effects, or prior authorization denial). They've heard Jardiance causes weight loss and wonder if it's a substitute. Answer: it's not. The weight loss is 3 to 4 times smaller, and Jardiance isn't approved for obesity.

Group 3: People considering combination therapy. These users are already on a GLP-1 and searching whether adding Jardiance will boost results. Answer: possibly, if you have diabetes. The mechanisms are additive, but the incremental benefit is small (3 to 5 additional pounds) and requires a diabetes indication to justify the prescription.

The mismatch between search intent and clinical reality explains why "Jardiance weight loss" has high search volume despite limited evidence. Users are pattern-matching the phrase "weight loss" without understanding mechanism or magnitude.

What most articles get wrong about SGLT2 inhibitor weight loss

Common error: treating all weight-loss mechanisms as equivalent.

Most consumer health articles list Jardiance alongside GLP-1 agonists as "diabetes medications that cause weight loss" without explaining that the magnitude differs by a factor of three to four. This creates false equivalency.

The correct framing: SGLT2 inhibitors cause modest weight loss as a secondary metabolic effect. GLP-1 agonists cause substantial weight loss as a primary pharmacologic effect. The former is a side benefit in diabetes management; the latter is the therapeutic target in obesity treatment.

Common error: citing percentage weight loss without absolute context.

Some articles report "2 to 3% body weight loss" for Jardiance, which sounds comparable to early GLP-1 data. But that's 2 to 3% at 24 weeks, where GLP-1 agonists are producing 8 to 12% at the same timepoint and continue to 15 to 20% at 68 weeks. The plateau matters.

Common error: ignoring the kidney-function dependency.

SGLT2 inhibitors require functioning kidneys to work. Efficacy drops sharply below an eGFR of 45 mL/min/1.73m² and is negligible below 30. Roughly 15% of U.S. adults over 60 have chronic kidney disease stage 3 or worse. For this population, SGLT2 inhibitors won't cause meaningful weight loss even if prescribed.

GLP-1 agonists work independently of kidney function (though dose adjustment is needed in severe renal impairment for exenatide). The mechanism doesn't rely on filtration or excretion.

The plateau problem: why weight loss stops after 12 to 16 weeks

The Jardiance weight-loss curve is front-loaded. Most of the loss happens in weeks 4 to 12, then flattens.

Three reasons:

1. Metabolic adaptation to caloric deficit. When you lose 240 to 360 calories per day through glucose excretion, your body compensates by reducing energy expenditure and increasing hunger signaling. Within 12 to 16 weeks, most patients unconsciously eat slightly more or move slightly less, offsetting the glucose loss. This is the same adaptation that occurs with any caloric restriction.

2. Reduction in filtered glucose load. As blood glucose improves (the intended diabetes effect), less glucose is available to be filtered and excreted. A patient starting with an HbA1c of 9% and fasting glucose of 200 mg/dL has more glucose to excrete than the same patient 12 weeks later with an HbA1c of 7% and fasting glucose of 130 mg/dL. The drug is working for diabetes, but that success reduces the weight-loss effect.

3. Fluid vs fat loss composition. Some of the early weight loss is osmotic diuresis (water loss from glucose pulling fluid into urine). This accounts for 1 to 2 pounds of the initial drop and doesn't continue. The remaining loss is fat and lean mass, which plateaus as metabolic adaptation occurs.

GLP-1 agonists don't plateau as sharply because appetite suppression continues as long as the drug is active. The mechanism doesn't depend on substrate availability (glucose) or create the same degree of metabolic compensation.

When Jardiance makes sense and when it doesn't

Jardiance makes sense when:

• You have type 2 diabetes and need glucose control. The weight loss is a bonus, not the primary goal.
• You have heart failure with reduced ejection fraction. SGLT2 inhibitors reduce hospitalization and mortality risk independent of weight loss (EMPEROR-Reduced trial).
• You have diabetic kidney disease. SGLT2 inhibitors slow progression of albuminuria and preserve kidney function (EMPA-KIDNEY trial).
• You're already on a GLP-1 and have diabetes. Adding Jardiance can provide complementary metabolic benefits (glucose excretion plus appetite suppression).

Jardiance doesn't make sense when:

• Your primary goal is weight loss and you don't have diabetes. The magnitude is too small to justify the cost, side-effect risk, and off-label use.
• You have chronic kidney disease stage 3B or worse (eGFR below 45). The drug won't work effectively.
• You're seeking a GLP-1 alternative due to cost. Jardiance is not cheaper. The retail price is $600 to $700 per month without insurance, comparable to brand-name GLP-1 agonists.
• You have recurrent urinary tract infections or genital yeast infections. SGLT2 inhibitors increase glucose in the urogenital tract, which raises infection risk.

The pattern we see in FormBlends consultations:

Patients ask about Jardiance when they've been denied prior authorization for semaglutide or tirzepatide, or when they've experienced intolerable nausea on a GLP-1. The hope is that Jardiance offers a "side-effect-free" weight-loss path.

The reality: Jardiance has a different side-effect profile (genital infections, polyuria, orthostatic hypotension), not a better one. And the weight-loss magnitude doesn't justify switching from a GLP-1 unless diabetes or heart failure creates a separate indication.

The appropriate clinical question isn't "Jardiance or GLP-1?" It's "Do I have a condition where Jardiance is indicated, and is weight loss a secondary benefit?" If the answer is no, pursuing Jardiance for weight loss alone is off-label use without supporting evidence.

The combination question: can you take Jardiance with a GLP-1?

Yes, and the combination is increasingly common in type 2 diabetes management.

Evidence for combination therapy:

The SUSTAIN 9 trial (cited earlier) demonstrated that semaglutide added to background SGLT2 inhibitor therapy produced additive weight loss and glucose control. The mechanisms don't interfere with each other.

A 2023 real-world analysis of 2,847 patients on combination therapy (GLP-1 + SGLT2 inhibitor) vs monotherapy showed:

• GLP-1 alone: -6.2 kg (-13.7 lbs) at 52 weeks
• SGLT2 inhibitor alone: -2.8 kg (-6.2 lbs) at 52 weeks
• Combination: -8.1 kg (-17.9 lbs) at 52 weeks

The combination effect is roughly additive, not synergistic. You get the full GLP-1 benefit plus most of the SGLT2 benefit (Blonde et al., Diabetes Therapy, 2023).

Who benefits from combination therapy:

Patients with type 2 diabetes who need both glucose control and cardiovascular or renal protection. The weight loss is a tertiary benefit.

Patients on GLP-1 monotherapy who have plateaued and need additional glucose lowering. Adding an SGLT2 inhibitor can reduce HbA1c by an additional 0.5 to 0.8 percentage points.

Who doesn't benefit:

Patients without diabetes seeking to maximize weight loss. The incremental 3 to 5 pounds from adding Jardiance doesn't justify the cost and side-effect risk when the GLP-1 is already doing the heavy lifting.

Patients with eGFR below 45. The SGLT2 inhibitor won't contribute meaningfully.

Insurance coverage for combination:

Most insurers cover GLP-1 + SGLT2 inhibitor combination when both are used for FDA-approved diabetes indications. Coverage is unlikely when the GLP-1 is prescribed off-label for obesity and Jardiance is added solely to boost weight loss.

Side effects that matter for weight-loss seekers

SGLT2 inhibitors have a distinct side-effect profile. If you're considering Jardiance primarily for weight loss, these are the effects that will determine tolerability:

Genital yeast infections (10 to 15% of patients). Glucose in urine creates a growth medium for Candida species. Women are affected more than men. Recurrent infections are common enough that some patients discontinue treatment. Preventive measures (hygiene, cotton underwear, probiotics) help but don't eliminate risk.

Urinary tract infections (8 to 10% of patients). Same mechanism. Glucose in the urinary tract promotes bacterial growth. Patients with a history of recurrent UTIs should weigh this carefully.

Polyuria and polydipsia (increased urination and thirst). Glucose pulls water into the urine (osmotic diuresis). Patients urinate more frequently and feel thirstier. This is most noticeable in the first 2 to 4 weeks and usually improves as the body adapts. Nighttime urination (nocturia) bothers some patients enough to discontinue.

Orthostatic hypotension (low blood pressure when standing). SGLT2 inhibitors cause mild volume depletion. Patients on blood pressure medications or diuretics are at higher risk. Dizziness when standing up is the common presentation.

Diabetic ketoacidosis (rare but serious). SGLT2 inhibitors can trigger euglycemic DKA (ketoacidosis without extremely high blood glucose). This is rare (fewer than 1 in 1,000 patients) but serious. Risk factors include very low carbohydrate intake, prolonged fasting, illness, or surgery. Patients following ketogenic diets should be monitored closely.

Fournier's gangrene (extremely rare but severe). Necrotizing fasciitis of the perineum. Fewer than 200 cases reported worldwide across all SGLT2 inhibitors since 2013. The FDA added a black-box warning in 2018. Symptoms include fever, perineal pain, swelling, and redness. Emergency surgical care is required.

Comparison to GLP-1 side effects:

GLP-1 agonists cause nausea, vomiting, diarrhea, and constipation in 30 to 50% of patients, but these are usually transient and improve after titration. SGLT2 inhibitor side effects (infections, polyuria) are less likely to resolve with continued use.

The side-effect trade-off: GLP-1 agonists have higher overall side-effect rates but most are temporary. SGLT2 inhibitors have lower rates but the effects that do occur (infections) tend to persist or recur.

The decision tree: SGLT2 inhibitor, GLP-1, or both

Start here: Do you have type 2 diabetes?

No → GLP-1 agonist is the appropriate choice for weight loss.

• Semaglutide (Wegovy 2.4 mg or compounded) or tirzepatide (Zepbound or compounded) are FDA-approved for obesity and produce 3 to 4 times more weight loss than Jardiance.
• SGLT2 inhibitors are not FDA-approved for obesity and lack supporting trial evidence in non-diabetic populations.
• Insurance is more likely to cover a GLP-1 for obesity than an off-label SGLT2 inhibitor.

Yes → Do you have heart failure or chronic kidney disease?

Yes → SGLT2 inhibitor (Jardiance or dapagliflozin) is indicated for cardiovascular or renal protection. Weight loss is a secondary benefit.

• The EMPEROR-Reduced and DAPA-HF trials showed mortality benefit in heart failure independent of diabetes status.
• The EMPA-KIDNEY trial showed slowed kidney disease progression.
• Adding a GLP-1 for additional weight loss and glucose control is reasonable if you're not at goal.

No → Do you need more than 10 to 15% total body weight loss?

Yes → GLP-1 agonist is the first choice.

• SGLT2 inhibitors won't get you there. The plateau at 2 to 3% body weight loss is consistent across trials.
• Start with semaglutide or tirzepatide. Add Jardiance later if glucose control is inadequate on the GLP-1 alone.

No → Is your primary goal glucose control with modest weight loss as a bonus?

Yes → Either class works, but consider starting with SGLT2 inhibitor if:

• You have a history of GI intolerance to other medications (SGLT2 inhibitors have lower nausea rates)
• You have cardiovascular risk factors (SGLT2 inhibitors reduce heart failure hospitalization)
• You have early kidney disease (albuminuria, eGFR 45 to 90)

Add a GLP-1 later if:

• HbA1c remains above goal on SGLT2 inhibitor alone
• You want additional weight loss beyond the initial 5 to 7 pounds
• You develop progressive kidney disease (GLP-1 agonists also have renal benefits per the FLOW trial)

FAQ

Does Jardiance cause weight loss? Yes. Jardiance causes modest weight loss averaging 4 to 7 pounds over 24 weeks by forcing the kidneys to excrete 60 to 90 grams of glucose per day in urine. The weight loss plateaus after 12 to 16 weeks and is substantially smaller than GLP-1 receptor agonists.

How much weight can you lose on Jardiance? Clinical trials show an average of 2 to 3% of total body weight over 6 months. For a 200-pound person, that's 4 to 6 pounds. The 25 mg dose produces slightly more loss than the 10 mg dose. Weight loss stops after 12 to 16 weeks.

Is Jardiance approved for weight loss? No. Jardiance is FDA-approved for type 2 diabetes, heart failure, and cardiovascular risk reduction. It is not approved for obesity or weight management. Prescribing it primarily for weight loss is off-label use.

Is Jardiance better than Ozempic for weight loss? No. Semaglutide (Ozempic, Wegovy) produces 3 to 4 times more weight loss than empagliflozin in head-to-head comparisons. At 26 weeks, semaglutide causes 10 to 12 pounds of loss vs 4 to 6 pounds for Jardiance. The mechanisms are different: semaglutide suppresses appetite, Jardiance excretes glucose.

Can I take Jardiance and a GLP-1 together? Yes, if you have type 2 diabetes. The combination is common in diabetes management and produces additive weight loss (roughly 3 to 5 additional pounds beyond GLP-1 alone). Insurance typically covers the combination for diabetes indications but not for obesity alone.

Why does Jardiance cause weight loss? Jardiance blocks SGLT2 proteins in the kidney, preventing reabsorption of filtered glucose. The glucose is excreted in urine instead of being metabolized. This creates a passive caloric deficit of 240 to 360 calories per day, leading to gradual weight loss.

Does Jardiance work for weight loss if I don't have diabetes? The medication will still cause glucose excretion, but the effect is smaller in people with normal blood glucose. Most trials enrolled diabetic patients with elevated baseline glucose. Efficacy in non-diabetic obesity is unknown, and the medication is not approved for this use.

What are the side effects of Jardiance for weight loss? The most common side effects are genital yeast infections (10 to 15%), urinary tract infections (8 to 10%), increased urination, and increased thirst. Rare but serious risks include diabetic ketoacidosis and Fournier's gangrene. These side effects occur regardless of whether you're taking Jardiance for diabetes or weight loss.

How long does it take to lose weight on Jardiance? Most weight loss occurs in the first 12 to 16 weeks. Patients typically notice a 2 to 4 pound drop in the first month, with gradual additional loss through month 3 or 4. After that, weight stabilizes and further loss is uncommon.

Will I gain the weight back if I stop Jardiance? Possibly. The weight loss is maintained only as long as you continue the medication. Stopping Jardiance eliminates the glucose excretion mechanism, and most patients regain 50 to 75% of the lost weight within 6 months. This is similar to other weight-loss medications.

Can Jardiance cause dehydration? Yes. The glucose in urine pulls water with it (osmotic diuresis), leading to increased fluid loss. Patients should drink adequate water, especially in hot weather or during exercise. Signs of dehydration include dizziness, dry mouth, and dark urine.

Is Jardiance cheaper than GLP-1 medications? No. Retail price for Jardiance is $600 to $700 per month without insurance, comparable to brand-name Ozempic or Wegovy. Compounded semaglutide or tirzepatide through platforms like FormBlends is typically $200 to $400 per month, making compounded GLP-1 agonists the more affordable option for weight loss.

Sources

1. Zinman B et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015.
2. Anker SD et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021.
3. Zinman B et al. Efficacy and Safety of Semaglutide Once Weekly vs Placebo as Add-On to SGLT-2 Inhibitors in Type 2 Diabetes (SUSTAIN 9). Diabetes Care. 2019.
4. Patel DK et al. Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Body Weight in Type 2 Diabetes: Systematic Review and Meta-Analysis. Diabetes, Obesity and Metabolism. 2022.
5. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
8. Blonde L et al. Real-World Outcomes of Combination Therapy with GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes. Diabetes Therapy. 2023.
9. Herrington WG et al. Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY). New England Journal of Medicine. 2023.
10. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine. 2024.
11. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
12. FDA Drug Safety Communication. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. 2018.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
14. Vallon V et al. SGLT2 Inhibitors: Mechanisms of Action in the Kidney. Annual Review of Physiology. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Jardiance is a registered trademark of Boehringer Ingelheim. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.